Wednesday, February 28, 2007


New BIO Survey Counters Claims Regarding Single Source Therapies ...
Genetic Engineering News (press release) - New Rochelle,NY,USA The Biotechnology Industry Organization (BIO) today released a study which found that Medicare Part D plans offer significant discounts on single-source ...

Inkjet Tissue Engineering
By Mike Treder
A recurring theme on FuturePundit is that the use of computer industry technologies to perform biological manipulations will make biotechnology increasingly advance at the rate of computer technology. We all know that's a really fast ...

In the fast lane
Express Pharma - Mumbai,India
Biotechnology has made rapid strides over the last two decades, emerging as a driving force of radical innovation. The chemical paradigm of drug discovery ...

Big Cities Tops for Bioscience Jobs - New York,NY,USA
... in the biosciences are New York and Los Angeles, according to the study prepared by Battelle on behalf of the Biotechnology Industry Organization.

DuPont reinvests to focus on biotechnology and genetics Truth about Trade & Technology - Des Moine,IA,USA The reinvestment, designed to boost the company's plant genetics and biotechnology platforms, comes after an aggressive reorganization strategy in its ...

Arizona Biotech

Today’s Pick: Biotechnology: biggest money-losing industry in history By webgoddesscathy @ MaRS Biotechnology has been “one of the biggest money-losing industries in the history of mankind,” says Genentech CEO Arthur D. Levinson. He estimates that the biotech industry as a whole has lost nearly $100 billion in the past three ...

University lists in United States for Biotechnology
Topic: Study Abroad Posted By: zankhana_shah0 Post Time: Feb 27, 2007 at 03:03 AM.


Biotechnology companies seek UC Davis students The California Aggie Online - Davis,CA,USA Over the last 20 years, few industries have grown as quickly or shown as much promise as the biotechnology industry. With a wide range of services and ...

2007 BIO International Convention Set to Bring the World to Boston (press release) - Newtown,PA,USA The 2007 BIO International Convention, sponsored by the Biotechnology Industry Organization (BIO) will take place May 6-9, 2007 at the Boston Convention and ...

Icos’ arc from rising to fallen star is sadly typical for local ...
Washington CEO - Seattle,WA,USA
Bruce LA Carter, CEO and chairman of ZymoGenetics Inc., leads what is now the largest independently owned biotechnology firm in Washington. ...

HQ's CEO Will Be Guest Speaker at Bio International Convention Market Wire (press release) - USA The Convention serves to educate the public and policymakers about biotechnology, while fostering partnering meetings and other business development ...

Arizona Biotech

Recent Call by President Bush for the Increased Production of ... (Pressemitteilung) - Wien,Austria US President, George Bush, is looking to the biotechnology industry to increase the domestic production of biofuels and the knock-on effect could mean more ...

BioCrossroads Makes Impact on Life Sciences Industry Inside INdiana Business (press release) - Indianapolis,IN,USA Reputation as a national life sciences leader validated by outside experts, including the Biotechnology Industry Organization (BIO) and Battelle Memorial ...

Biotech News

Court upholds Calif. stem cell agency (AP) By Yahoo! News: Biotechnology News AP - California's $3 billion stem cell agency withstood another challenge to its constitutionality when a state appeals court rejected claims by abortion foes and anti-tax advocates that the agency's managers had conflicts of interest.

NIH Biotechnology Seminar Series
Institute of Biosciences and Bioengineering Speaker: Raymund Eich Tuesday, March 20, 2007 10:30 AM to 11:30 AM 102 Keck Hall Rice University 6100 Main St Houston, Texas, USA.

Arizona Biotech

best colleges for marsters degree in biotechnology abroad
Topic: Biology Posted By: richa_shivani Post Time: Feb 25, 2007 at 11:16 PM.

Thierry Desmaris Appointed Vice President of Corporate Development serves the refining, upstream oil and gas, LNG and gas-to-liquids, petrochemicals, chemicals, power, pharmaceuticals, biotechnology and healthcare industries. The corporation is based in Hamilton, Bermuda, and its operational ...

Biotechnology News

Sector Wrap: Biotechnology
BusinessWeek - USA
Shares of biotechnology companies fell sharply Tuesday, caught up in the severe downturn that punished all but a few shares in the US stock markets.

Time Lapse Video Shows Value of Drought Stress Corn Truth about Trade & Technology - Des Moine,IA,USA A new time lapse video on the bottom of the Growers for Biotechnology web site – – compares corn with and without genetics ...

Palatin Strikes a Landmark Deal
NJBIZ - New Brunswick,NJ,USA
CRANBURY - Small biotechnology firm Palatin Technologies of Cranbury has signed a deal with pharmaceutical powerhouse AstraZeneca to develop and sell drugs ...

Sunday, February 25, 2007

Biotech news

‘Incentives necessary to foster biotech research’
Financial Express - Bombay,India
India’s pharmaceutical and biotech sectors are in the midst of frenzied action – setting up of joint ventures, research centres and even buyouts by Indian ...

Biotech in Review: Genentech Extends Uses for Avastin and Xeloda Seeking Alpha - New York,NY,USA Centient Biotech Investor submits: Roche (RHHBY) and its majority-owned US partner Genentech (DNA) reported that European authorities recommended approval ...

Generic biotechs may be on way
Chicago Tribune - Chicago,IL,USA
And opening the door to generic biotech drugs would save even more. Some of the drugs, like the anti-anemia drug Epogen, can cost more than $10000 a year ...

Interview with Jim Greenwood, President, Biotechnology Industry ...
By George Elvin
... which represents over one thousand biotechnology companies and related organizations, talks about what it takes to bring today’s biotech breakthroughs to market, and how they are leading the move toward clean energy.

Biotech News

PREMIER Biosoft and PamGene International BV form an alliance PREMIER Biosoft International announced an alliance with PamGene International BV to develop a software product for designing custom MLPA® oligonucleotide probes for use with PamChip® ... daily News from Biotech-...

Biotech player searching for the magic bullet Therapeutics Daily (subscription) (press release) - Newtown,PA,USA BIOTECH Novogen is developing pharmaceutical and nutriceutical agents based on the company's patented isoflavonoid platform technology. ...

Biotech SMEs seek service tax sops
Therapeutics Daily (subscription) (press release) - Newtown,PA,USA Large biotech companies focus on price (of drugs and vaccines) controls, research and development sops, improved and more transparent functioning of ...

Pharmaceutical Grade Filter Media
... File located at the US Food and Drug Administration Center for Drug Evaluation and Research (CDER), providing the confidence you require when using ErtelAlsop Zeta-Pak® elements in your critical pharmaceutical or biotech applications.

Sayings Quotes Blogs

Friday, February 23, 2007

BIO Analysis - Biologics Studies Are Based on Flawed Assumptions

Express Scripts and PCMA Follow-On Biologics Studies Are Based on Flawed Assumptions That Undermine Their Credibility: BIO Analysis Raises Serious Concerns Over Two Cost Savings Studies

WASHINGTON--(BUSINESS WIRE)--Feb 22, 2007 - Two recent studies examining potential savings in health care costs resulting from the establishment of a pathway for regulatory approval for follow-on biologics contain significant flaws and assumptions that call into serious doubt their validity, said the Biotechnology Industry Organization (BIO) today in an analysis of two separate studies released by the Pharmaceutical Care Management Association (PCMA) and by Express Scripts.

"As a result of numerous flawed assumptions, and the lack of any credible evidence to support these alleged savings, we believe these studies should be rejected as unscientific and unreliable," stated BIO President and CEO Jim Greenwood.

"This debate should be focused on and driven by credible science, fact-based studies and patient safety. These studies fail to meet these standards. They cannot be relied upon in lieu of a more rigorous analysis," stated Greenwood. "Congress should recognize these flaws and misleading assumptions and reject these studies as it evaluates proposals regarding follow-on biologics."

The BIO analysis details nine serious flaws in the PCMA and Express Scripts that call into serious doubt the validity of their claimed savings. These flaws include:

-- Assumptions about patent expirations that are inconsistent with credible analyst reports seriously call into question more than $40 billion of the alleged savings cited by the Express Scripts study;

-- Calculation errors in the PCMA study result in an overestimate of savings of 40 percent, even taking their other assumptions as correct;

-- Internally inconsistent allegations of interchangeability in the Express Scripts study call into question an additional $13.8 billion in alleged potential savings;

-- Presuming that a pathway under one law would generate savings for products approved under another law calls into question over $17 billion in additional alleged savings in the Express Scripts study;

-- Market penetration rates for follow-on biologics incorrectly modeled on generic drug experience are inconsistent with credible published analyses;

-- Calculations based on determinations of interchangeability that include presumption of savings beginning in 2007 are unsupported in both studies.

"No credible analysis of follow-on biologics suggests that we will see anything close to the savings we've seen from generic drugs, nor any savings close to the flawed estimates claimed in these studies," stated Ted Buckley, Ph.D, BIO's Director of Economic Policy. "As leading health economists have pointed out, the traditional generic drug business model is simply inapplicable when dealing with these complex biological products."

BIO's analysis details flaws in the PCMA and Express Scripts studies regarding claims of immediate savings from follow-on biologics. The assumption made in both studies that follow-on products will be promptly rated as interchangeable by the FDA and that as a result market substitution will occur rapidly ignores existing regulatory, scientific and market experience.

In fact, as noted in BIO's analysis, the U.S. Food and Drug Administration (FDA) has not determined how interchangeability can be established for complex proteins. FDA has stated that, "Different large protein products, with similar molecular composition may behave differently in people and substitution of one for another may result in serious health outcomes." According to the European Medicines Agency, "(d)ue to the complexity of biological/biotechnology-derived products the generic approach is scientifically not appropriate for these products."

The faulty assumption of interchangeability likely results in a significant overestimation of savings, as products not designated as interchangeable would very likely experience slower adoption rates. These differences do not appear to be taken into consideration in either the PCMA or the Express Scripts studies.

BIO's analysis also finds that both studies are based on dubious claims regarding patent expiration timelines leading to significant overestimates of savings. The Express Scripts report acknowledges that "additional patents have been granted, which may extend the protection of Procrit and Epogen," but then goes on to make the explicit assumption that, "This model assumes that these patents would not be a barrier to biogeneric entry in this therapeutic area." Using Express Scripts' own estimates, reliance on this unexplained assumption accounts for more than half of their total projected savings.

Furthermore, both studies also implausibly assume that the current market share of the biologics will not evolve over time, despite the fact that this has not been borne out by experience. "One of the basic facts of a dynamic marketplace is that products are replaced by newer, more innovative products," stated Buckley.

Finally, the PCMA study assumes that for every biologic that comes off patent there will be an associated follow-on product. There is no credible evidence to suggest that it is scientifically possible to develop a follow-on for every biologic that is currently on the market. Further, many biologics have a limited market, and therefore, it likely will be economically less attractive for companies to pursue manufacturing of follow-ons for many of these products.

"Overall, we find that these studies contain claims of potential savings based on a seriously flawed set of assumptions that defy current experience and lack credible evidence," concluded Greenwood. "Congress should move deliberately as it examines proposals to develop a pathway for follow-on biologics."

The full BIO analysis can be found at .

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the global event for biotechnology. -0- Upcoming BIO Events

-- 2007 World Congress on Industrial Biotechnology and Bioprocessing
March 21-24
Orlando, FL

-- BIO International Convention
May 6-9, 2007
Boston, MA

-- BIO VentureForum-East 2007
June 18-20, 2007
Montreal, Canada

-- BIO Mid-America VentureForum 2007
Sep. 24-26, 2007
Milwaukee, WI


Biotechnology Industry Organization (BIO)
Stephanie Fischer, 202-312-9263

Biotech News

Phoenix Arizona

Ten Years After Dolly, Animal Cloning Realizes Significant Milestones and Progress

Ten Years After Dolly, Animal Cloning Realizes Significant Milestones and Progress
Technology Poised to Begin Providing Consumers With Improved Products and Benefits

In the decade since scientists at Scotland’s Roslin Institute first announced that they had successfully cloned the first animal from an adult cell — a sheep named Dolly — animal cloning technology has substantially advanced and will soon begin offering consumers innovative and unique products and benefits.

“Ten years ago today, there occurred a dramatic moment in the world of biotechnology when Dolly’s successful birth was announced,” said Jim Greenwood, president and chief executive officer of the Biotechnology Industry Organization (BIO). “Since Dolly, animal cloning technology has advanced significantly. Researchers have developed improved and safer cloning techniques that have resulted in normal births of healthy animal clones, and we are now applying this technology to a variety of applications. Today we are poised to utilize this technology to enhance food production, food security in developing countries, the health of farm animals and the safety of our food supply. Cloning will also tackle the challenge of the extinction of wild animals like the giant panda.”

Dolly was the first mammal to be successfully cloned using somatic cell nuclear transfer (SCNT) technology. This technique makes it possible to produce multiple animals from a single donor, and involves transferring the genetic information from a cell from the body of an animal into an empty oocyte, or egg. This process results in an embryo, which is implanted into a surrogate mother, who carries the pregnancy to term.

Animal cloning is an assisted reproductive technology that allows livestock breeders and farmers to produce identical twins of their best animals. In December 2006, the U.S. Food and Drug Administration (FDA) released a draft risk assessment which concluded that meat and milk products from animal clones and their offspring are safe for human consumption, and are no different from foods produced through other breeding methods. While currently there are no known products from animal clones and their offspring on the market, in the future, consumers will benefit from a healthier, consistent, and more abundant meat and milk supply produced from animal cloning.

In the decade since Dolly’s birth, scientists have successfully cloned over a dozen other species. These include cows, goats, pigs, horses, mules, deer, mice, cats, dogs, and rare and endangered species including the mouflon, gaur, banteng, and African wildcat. These advances were made possible by significant improvements in cloning techniques, which have also resulted in a decrease in unique health risks to animal clones. Decades of research and improvement in cloning techniques have resulted in the production of animal clones that are as healthy as conventional animals and those conceived through other forms of assisted reproductive technology.

“Cloning technology has enormous potential to positively impact the world in which we live,” Greenwood stated. “This technology gives us the opportunity to increase community health and well-being by providing people in developing countries with greater access to protein-rich animal food products. Farmers have an opportunity to meet consumer demand for high quality and safe food that is available in a reliable and consistent manner and conservationists have a fighting chance to preserve endangered animal species.”

Scientific resources on animal cloning can be found at

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

Advance media registration for the BIO International Convention is now available online. Registration is complimentary for credentialed members of the news media. To register, please visit Reporters and editors working full-time for print or broadcast news organizations may register onsite with valid media credentials. All freelancers, college and online publications are strongly encouraged to register in advance by Friday, April 20, 2007.

Biotech News

Biotech News

Biotechnology Needs Urgent Investment, Warns Leading UK Scientist University of Ulster Online - Coleraine,UK Urgent investment into biotechnology is needed if we are to cure diseases such as cancer and Alzheimer’s – that was the message from leading science ...

Biotech Leaders to Confront Industry Issues at Milan Conference ...
dBusinessNews San Jose (press release) - San Jose,CA,USA San Jose - Carlsbad, CA and Munich, Germany, February 20, 2007 – EBD Group today announced that on Monday, March 5, international biotechnology industry ...

Famous Quotes

MONMOUTH UNIVERSITY TO HOST SANOFI-AVENTIS 2007 BioGENEius CHALLENGE Monmouth University News & Events - West Long Branch,NJ,USA Under the direction of the Biotechnology Institute, the national organization dedicated to biotechnology education, the sanofi-aventis BioGENEius awards are ...

The Site Provides Tips And Advice On Getting A ...
Eworldwire (press release) - Succasunna,NJ,USA Biotechnology career site offers job hunting and career advancement advice to jobseekers in the backdrop of recent job cuts in the sector. LONDON, Ala. ...

w" color="#0000FF" size=2>>

Journal of Plant Biochemistry and Biotechnology By Marcus(Marcus) This journal is an official organ of the Society for Plant Biochemistry and Biotechnology, Division of Biochemistry, Indian Agricultural Research Institute, New Delhi 110012, India, and is published twice a year (January and July), ...

Marcus P. Zillman, MS, AMHA Author/Sp...

Surprise £68m cut in research funding
By helger(helger)
The Biotechnology and Biological Sciences Research Council (BBSRC) responded to the announcement by revealing it would need to cut £6.7m from its spending plans. BBSRC said it expected to reduce the equivalent of 20 new grants, ...

Famous Quotes

Wolpert and Fuller debate ID at University of London ID would likely re-orient biology and make biotechnology and bioengineering more prominent. ID is more optimistic than evolution about what human intelligence can achieve. It is not a science stopper but assures us that we can ...

Shire to Purchase New River Pharma for $2.6 Billion By admin New River Pharmaceuticals Inc., based in Radford, Virginia, announced that it has signed a definitive agreement with Shire plc under which Shire has agreed to acquire New River. Shire will pay $64.00 in cash for each share of NRPH ...

Virginia Biotechnology Association

Biotechnology | Roses are blue, violets are red | By noteworthy Mere colour is for unsophisticated lovers. A truly harmonious Valentine gift should smell beautiful as well. Sadly, commercial varieties of cut rose lack fragrance. This is because there is a trade-off between the energy that plants ...

MemeStreams Top URLs

Access Pharmaceuticals to Acquire Somanta Pharmaceuticals By bhartzer Somanta is an Irvine, California based biotechnology company with four novel anti-cancer compounds in development, one of which is currently in Phase 2 clinical trials. Channel: Health & Fitness Tags: Access Pharmaceuticals Somanta ...

Biotech Leaders to Confront Industry Issues at Milan Conference ...
San Jose - Carlsbad, CA and Munich, Germany, February 20, 2007 – EBD Group today announced that on Monday, March 5, international biotechnology industry leaders will descend on Milan, Italy, for BIO-Europe Spring (March 5-7) to discuss ...

DBusiness News - San Jose

Pharmaceutical, Biotechnology and Medical Device Industries With Bio-Imaging Technologies

Support Product Development in the Pharmaceutical, Biotechnology and Medical Device Industries With Bio-Imaging Technologies Live on
February 22, 2007 -- Mark L. Weinstein, President and Chief Executive Officer of Bio-Imaging Technologies, Inc. (NASDAQ: BITI), will be joining Market News First ( for an exclusive live interview with MN1's Saul Albom. The interview is scheduled for Thursday, Feb. 22, 2007, at 12:30pm CDT.

Operation in the U.S., Bio-Imaging provides services that support product development process of pharmaceutical, biotechnology and medical device industries. It operates in two segments: Pharmaceutical Contract Services and CapMed division. Pharmaceutical contract service segment provides services that support the product development process of the pharmaceutical, biotechnology and medical device industries. CapMed segment provides software application that enables users to manage and store personal health information, like the medical images, drug information, patient education and disease guidelines.

During the interview, Mr. Weinstein will be discussing Bio-Imaging's recently released Fourth Quarter and Year-End 2006 Financial Results. "In 2006 we solidified our core Clinical Trials Business and made good progress in our CapMed Division. We returned the company to profitability and ended the year with a record backlog," stated Mr. Weinstein. "Fourth quarter 2006 service revenues of $8.6 million represented a 7% sequential quarter over quarter increase. The increased profitability on these revenues is a testament to our leverageable expense base that generally provides increasing margins as we grow our revenues."

Join Mr. Weinstein to learn more about the goals of the company, as well as its position in the stock market.

About Bio-Imaging Technologies

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab in Newtown, PA, its European Core Lab in Leiden, The Netherlands and its recent acquisition of Theralys SA in Lyon, France. Through its CapMed division, Bio-Imaging provides the Personal HealthKey™ technology and the Personal Health Record (PHR) software allowing patients to better monitor and manage their health care information. Copies of Bio-Imaging Technologies' press releases and other information may be obtained through Bio-Imaging's web site at


Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live radio web site that brings real market news to investors and features live interaction with companies from the AMEX, NYSE, NASDAQ, Over the Counter Bulletin Board and the Pink Sheets.

Through daily, live commentary we keep you up to date on the companies you invest in along with what's going on in the stock markets by the second.

President Bush's Visit to North Carolina

President Bush's Visit to North Carolina Highlights Key Role for ...
Autochannel (press release) - USA
WASHINGTON--The Biotechnology Industry Organization (BIO) thanked President Bush for his participation in a panel discussion on advances in industrial ...

A 2001 Genentech biotechnology patent is revoked International Herald Tribune - France NEW YORK: The US Patent and Trademark Office has revoked a fundamental biotechnology patent held by Genentech, the biotechnology company that was at the ...

Jesup & Lamont Initiates Coverage of Generex Biotechnology With ...
Genetic Engineering News (press release) - New Rochelle,NY,USA Jesup & Lamont, a New York-based full-service brokerage and investment banking firm, announced today that it has initiated coverage of Generex Biotechnology ...

MCI invests in biotechnology
Polish Market - Warsaw,Poland
BioVentures, which will be involved in biotechnology investments and medical firms in the early stages of development, ie seed and start-up companies. ...

SARTORIUS - Creation of Sartorius Stedim Biotech

SARTORIUS - Creation of Sartorius Stedim Biotech - interviews

Date : Thursday, February 22, 2007

Video interviews available now on with Dr Joachim Kreuzburg, CEO, Sartorius AG, and Bernard Lemaître, Chairman, Stedim SA

* Strategic rationale

* Deal structure and financing

* Valuation

* Business synergies

* The combined company

* Next steps

This programming is available in video, audio and transcript. It's free to view. All you need to do is register at is an online financial website where top management of companies address the critical issues facing their businesses

Wednesday's Top Biotech and Medical Stocks By 24/7 Wall St.

Biotech News

Pittsburgh-area Biotech businessman accused of mail fraud Leader Times - Kittanning,PA,USA By AP. A Pittsburgh-area businessman paid kickbacks to a manager at a Milwaukee company to increase his sales, federal prosecutors allege in a grand jury ...

Leading Regenerative Medicine Researcher Dr. Anthony Atala to ...
dBusinessNews Triangle (press release) - Raleigh,NC,USA The 16th annual Biotech conference – scheduled for May 14-15, 2007, at the Marriott at the Civic Center in Durham, NC – is presented by CED in partnership ...

Genentech Takes Hit On Avastin Success
By (Richard Daverman,...
In a European trial, Avastin increased the progression-free survival of patients with non-small cell lung cancer. But the results included an unexpected kicker: Avastin was just as effective at the low dose as one that was twice as ...

The Centient Biotech Investor

Enigma Diagnostics appoints Biresh Roy as Chief Financial Officer Enigma Diagnostics announced the appointment of Mr Biresh Roy as Chief Financial Officer (CFO). Mr Roy, 44, will join the Board as an Executive Director. He is a strategically-oriented CFO with a ...

daily News from Biotech-...

The Biotech Industry, Genzyme & The Cure - Part V This article is the final installment of a five-part series focusing on the biotech industry, Genzyme and Pulitzer Prize-winning reporter Geeta Anand’s book The Cure. Please click here to learn more about this series. ...

Biotech News

Seattle Biotech Ikaria Merging With New Jersey Firm Black Enterprise - New York,NY,USA ... called Ikaria Holdings raised $300 million in venture capital, which investors are characterizing as possibly the largest biotech financing in history. ...

Biotech businessman accused of paying kickbacks, mail fraud Belleville News-Democrat - Belleville,IL,USA AP. PITTSBURGH - A Pittsburgh-area businessman paid kickbacks to a manager at a Milwaukee company to increase his sales, federal prosecutors allege in a ...

Biotech Day In Review: Genentech Loses Cabilly Patent Ruling Seeking Alpha - New York,NY,USA Centient Biotech Investor submits: Genentech (DNA) announced that the US Patent Office invalidated the Cabilly patent that protects its method for ...

Two Biotech Wizards Load up on Genomic Health - Point Roberts,WA,USA A 29% gain in Allos Therapeutics (ALTH), a biotech company that develops small molecule drugs for cancer treatments. Of course, this is just an incomplete ...

Teva reconsiders Hungarian biotech facility on drug law concern Budapest Business Journal - Budapest,Hungary Teva Pharmaceutical Industries Ltd., the world's biggest maker of generic medicines, is reconsidering a plan to build a biotech center in Hungary because of ...

BIOTECH STOCKS Biotech, pharma benchmarks move lower MarketWatch - USA BOSTON (MarketWatch) -- The biotech and pharmaceutical benchmarks moved lower early Thursday as shares of Genentech dipped on news that a study has found ...

Tuesday, February 20, 2007


International symposium at ASU will bring together scientists, entrepreneurs

TEMPE, Ariz. – Scientists, engineers and entrepreneurs working on the leading edge of nanotechnology will gather at Arizona State University for the international Nano and Giga Challenges Symposium, March 14 to 16, 2007.

Arizona Governor Janet Napolitano will give a welcoming address at 9 a.m. March 14, officially opening an event, which is expected to draw as many as 500 attendees from 50 nations to ASU’s campus in Tempe.

Phoenix Mayor Phil Gordon is scheduled to open the symposium sessions on the morning of March 16. Tempe Mayor Hugh Hallman is to address attendees on March 15.

Two Nobel Prize winners in science will be featured speakers at the event, among 200 presenters and more than 60 speakers from top universities and national laboratories in 30 countries, as well as major international companies such as Intel, Motorola and IBM.

Nobel Laureates to attend are John Polanyi, a professor at the University of Toronto, won a Nobel Prize in 1986 for research in chemistry, and physicist Nicolaas Bloembergen, who won the prize in 1981 for work in laser spectroscopy. Bloembergen is a professor emeritus of Harvard University and now visiting professor at the Arizona Center for Mathematical Sciences at the University of Arizona.

They will join colleagues from academia, industry and government to explore ways to apply “nano” or molecular (small-scale) devices to meet “giga” (gigantic) scientific and technological challenges.

“This conference will provide a rare forum that brings scientists together with entrepreneurs to examine ideas for how to take nanotechnology research and employ it for successful commercial ventures,” says Herb Finkelstein, industrial and government research liaison with ASU’s Ira A. Fulton School of Engineering.

The focus will be on efforts to spark advances in nano-scale electronic and optoelectronic devices, high-performance integrated circuits, sensor technology and molecular electronics and bioelectronics – progress that is crucial to meeting growing demand from industry, government and consumers for improved technologies.

“Nanotechnology is emerging as a major enabling solution for many of the world's technological problems,” says Herb Goronkin, president of Phoenix-based Technology Acceleration Associates and chair of the conference advisory board. "It touches on numerous areas of current research by providing unique solutions to the design, fabrication and performance of products that could not previously be manufactured.”

Academic and industrial researchers will present research papers on work to merge microelectronics, nanoelectronics and photonics in such areas as atomic-scale materials design, theory and experiment, bio- and molecular electronics and photonics, high frequency electronics, fabrication of nanodevices, magnetic materials and spintronics, materials and processes for integrated and subwave optoelectronics, nanoCMOS, new materials for FETs and other devices, nanoelectronics system architecture, nano optics and lasers, non-silicon materials and devices, and quantum effects in devices.

“Breakthroughs in nanotechnology will revolutionize products across the scientific and commercial spectrum, creating significant opportunities for innovative entrepreneurs,” Goronkin says.

“The Nano Giga Challenges conference is uniquely poised to mark the research transition from basic science of nanomaterials to creation of new functions and systems built upon those materials,” he says.

The event will boost Arizona’s burgeoning reputation as a promising center for science and technology innovation, said Stephen Goodnick, ASU associate vice president of research.

“It will showcase ASU’s nanotechnology program and bring visibility to a broad range of microelectronics and biotech industries in the Valley. It’s expected to generate more than $1 million for the local economy, but more importantly it should create a variety of business, research and educational opportunities in the Phoenix metropolitan area,” Goodnick said.

ASU is joined as organizer and head sponsor by Anatoli Korkin, president of Gilbert, Ariz.-based Nano and Giga Solutions, which provides consulting services in computational nanotechnology.

Korkin, a former senior scientist in Motorola’s research and development division, was a lead organizer for successful Nano Giga Challenges conferences in Moscow (in 2002) and Krakow, Poland (2004).

Among other prominent industrial research leaders scheduled to participate are Pahedon Avouris from IBM, Stan Williams from Hewlett Packard, Gianfranco Cerofolini from STM, George Maracas from Motorola, and Evgeni Gusev from Qualcomm, and academic research leaders, Mark Reed from Yale, Peidong Yang from the University of California at Berkeley, Konstantin Likharev from Stony Brook University, Markus Buttiker from the University of Geneva (Switzerland), Thomas Frauenheim from the University of Bremen (Germany), Hong Goo from McGill University (Canada), Hiroshi Iwai, from the Tokyo Institute of Technology (Japan), Israel Baumvol from the University of Rio Grande (Brazil), John Boland from Trinity College Dublin (Ireland), Dany Porath from the University of Jerusalem (Israel) and Ki-Bum Kim from Seoul National University (South Korea).

The ASU conference has already attracted sponsorship from the National Science Foundation, the Defense Advanced Research Projects Agency, the Office of Naval Research, the Office of Army Research, Oak Ridge National Laboratory, the City of Tempe, Motorola, Salt River Project utility company, the Arizona Technology Council and the Wernher von Braun Center for Advanced Research in Brazil.

Other sponsors include the International Science & Technology Center, STMicroelectronics, Quarles & Brady LLP law firm and JEOL Ltd., a world leader in electron microscopes.

The conference proceedings and other materials will be published by the Springer, Elsevier and Lithotech companies and the Institute of Physics. Media support is coming from the Arizona Department of Commerce, the Arizona Technology Council, the Greater Phoenix Economic Council, the Optics Industry Association and science news groups and several local, national and international science news groups and internet publishers.

For more information, go to

Sunday, February 18, 2007

Biotech Weblogs

Barron's: Biotech Clones
From Barron's 2-19-07: "Generic competition for Biotech firms like Amgen and Genzyme drew a step closer Wednesday, when a bipartisan group in Congress introduced a bill to authorize Food and Drug Administration approval of generic ...

‘India emerging as key biotech leader in Asia’
By boedipoetra
Projected to invest $80 million in 2007 to develop a national network of research laboratories, India tripled from the previous year the area it planted in biotech cotton, its first commercialised biotech crop in 2006. ...

IFTF: The reality of biotech
By moobalalala
New York Times reviews Gary Pisano's new book, Science Business: The Promise, the Reality, and the Future of Biotech. The big claim of Science Business is that contrary to popular perceptions (or perceptions within the biotech world), ...

Executive Assistant $40k+ - Biotech ( Oakland, CA US ) Challenging career position for executive assistant in stable, fortune 500, dynamic, prestigious biotech company. Experience interacting with executives and CFOs. Prefer individual who demonstrates attention to detail and is very ...

Job Bank USA - Available Jobs In: CA

Preliminary Trials s on PCV2 Swine Vaccine Kansas State University researchers have developed what appears to be a promising vaccine against Porcine Circovirus Type 2 (PCV2), a prevalent disease in swine herds in the United States. The trial results showed that in the finisher ...

The Biotech Weblog

Harbinger Research Issues Research Brief for Amazon Biotech Inc

Harbinger Research Issues Research Brief for Amazon Biotech Inc. With a Speculative Buy Rating and Price Target of $0.25
February 16, 2007 -- Harbinger Research LLC,, an independent research firm, issued a Research Brief today for Amazon Biotech, Inc. (OTCBB: AMZB), a development stage pharmaceutical/biotech company that is developing an all natural drug (AMZ 0026) for the treatment of HIV/AIDS.

The report provides a description of Amazon Biotech's business, industry, product, strategy, management team, and investment opportunities and risks. The report also includes a rating and price target.

The report is available free of charge at

About Harbinger Research, LLC:

Harbinger Research is a quality-leading New York based independent equity research company that provides insightful, in-depth equity research coverage and informational reports to smaller U.S. traded companies and the individuals and institutions that invest in them.

Amazon Biotech Inc.

For further information on Harbinger Research, please visit

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or following the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at:

Biotech News

Russia Approves Two Biotech Corn Varieties For Use in Animal Feed Grainnet - Decatur,IL,USA Russia's Federal Agency for Veterinary and Phytosanitary Control
(Rosselkhoznadzor) approved the two events, bringing the total number of biotech events ...

College, Covance in talks on biotech
Arizona Republic - Phoenix,AZ,USA
Those schools already offer classes in biotech. "When I look to the future, the best jobs for our kids are going to be in math and science," DePrez said. ...

Biotech resolution stirs controversy
High Plains Journal - Dodge City,KS,USA
The USWA board had already concluded their meetings when the biotech group met and the biotech committee expected them to pass the resolution. ...

Space for sprouting biotech next concern, supporters say Fort Pierce Tribune (subscription) - Fort Pierce,FL,USA ... and complementary medical firms near the research institutions is one of the next steps in building a successful research cluster, biotech backers say. ...

Biotech news

Feuerstein's Biotech Mailbag - USA
Welcome back to the "biotech mailbag." The response to this column has been great, so please keep the feedback coming. If you have questions about biotech ...

GPC Biotech Submits NDA For Lead Oncology Drug Candidate Satraplatin Medical News Today (press release) - UK In September 2006, GPC Biotech announced positive topline results from the double-blinded, randomized satraplatin Phase 3 registrational trial, ...

'India emerging as key biotech leader in Asia' - Jacksonville,FL,USA
Washington, Feb 17 (IANS) India is emerging as a key biotech leader in Asia, surpassing China for the first time in areas planted with biotech seed, ...

Thursday, February 15, 2007

Champions Biotechnology, Inc. Acquires Rights to Cancer Drug Candidates

Champions Biotechnology, Inc. Acquires Rights to Cancer Drug Candidates
Wednesday February 14, 3:17 pm ET

ARLINGTON, Va., Feb. 14 Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR - News), a development stage biotechnology company, announced today the acquisition of patent rights encompassing two Benzoylphenylurea (BPU) sulfur analog compounds that have shown promising potent activity against prostate and pancreatic cancer cell lines (Journal of Medicinal Chemistry, 2006, Vol. 49, No.7, 2357-2360). The acquired rights include pending U.S. Patent Application no. 11/673,519 and corresponding international patent application (PCT/US2006/014449) filed under the Patent Cooperation Treaty (PCT), both entitled Design and Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs.

These antimitotic inhibitors target MAPT (Microtubule-Associated Protein Tau) deficient tumors, a common feature of solid tumors, and have performed better than Docetaxel (Taxotere) in the difficult to treat direct patient xenograft models of pancreatic cancer (Journal of the National Cancer Institute, Vol. 99, Issue 2, January 17 2007, 105-107). The Company, in exchange for 550,000 restricted shares of its common stock, was assigned all the rights in the U.S. and in foreign countries to the applications for these inhibitors developed at Johns Hopkins University by their inventors Drs. Saeed Khan, Gurulingappa Hallur, Manuel Hidalgo and Antonio Jimeno.

This acquisition is the Company's initial step in building a biotechnology company from the ground up with a future portfolio of possible therapeutic drug candidates among other ventures that it is actively exploring. The Company plans to develop candidates from its portfolio of therapeutic compounds and partner with pharmaceutical and/or biotechnology partners for development, regulatory approval and marketing as appropriate.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. The Company generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors, which may include, but are not limited to, changes in general economic conditions, the ongoing threat of terrorism, ability to have access to financing sources on reasonable terms and other risks that are described in this document. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and the Company's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company's expectations, except as required by law.

Source: Champions Biotechnology, Inc.

Famous Quotes
Famous Quotes

New LMU Center To Support Nanotechnology Industry

New LMU Center To Support Nanotechnology Industry


Nanotechnology Center provides access to research and trainings on nanotechnology for the business, education and engineering communities

Loyola Marymount University has created an open education and research center to provide business, education and engineering communities with access to e-learning, conferences, seminars and information exchange programs about nanotechnology. Nanotechnology is the study devoted to the design and production of extremely small electronic devices and circuits built from individual atoms and molecules.

"Nano is just one more step in the history of technology that has and will change our lives," said John Wholihan, dean of LMU’s College of Business Administration. "Establishing the Nanotechnology Center at LMU allows our students to graduate recognizing the impact science will have on their business and personal lives."

The primary focus of the center is on the application and use of nanotechnology and its integration with the products that are manufactured today. Also, it is the foremost hub advocating the application and use of nanotechnology at the micro, nano and pico scales simultaneously.

Business and engineering students investigate nanotechnology that is being undertaken worldwide and locate and identify companies that are applying nanoscale technology. As an open education research system, the center shares its results and discoveries, and advocates collaboration in all of its activities.

"Our purpose is to complement other organizations and our competition is time," said Anthony Laviano, director of the Nanotechnology Center at LMU. "The understanding of nanotechnology will lead the way in tomorrow’s product strategy solution."

In order to fulfill this goal, the center offers a certificate program entitled "Essentials in Understanding and Managing Nanotechnology." Participants develop a working knowledge of nanotechnology and receive a top-level understanding of market and financial opportunities for application. Participants in the program must have a minimum of two years work experience and be internet literate.

Additionally, the center has developed curriculum at the high school, undergraduate and graduate levels. LMU will offer its first undergraduate course in nanotechnology in Fall ’07 and its first graduate course in Spring ’08. The high school curriculum will be used at the Don Bosco Technical Institute in Fall ‘07. The institute plans to build a new computer lab that will accommodate 40 students for future trainings.

The center also launched a partnership with the City of El Segundo to provide local businesses with immediate and skilled nanotechnology experts. The partnership is a model, developed with the hope of expanding to include all of Los Angeles County.

"The rapid advancement of nanotechnology is critical to El Segundo and its business community because many of our companies stake their futures on using the best technology available in their products and services," said Kelly McDowell, mayor of El Segundo. "We look forward to engaging LMU and our city in this enterprise and to attracting and growing new businesses focused on nanotechnology."

Laviano, who runs the center with a staff of four, has served on the National Academy of Sciences, National Research Council for Nanotechnology, and served as the LMU Frank R. Seaver College of Science and Engineering Chair for Nanotechnology. He received a B.A. from St. Charles College, Pa., an M.B.A. from Pepperdine University and a Ph.D. in business administration from Nova Southeastern University, Fla.

Laviano is also the founder and executive director of NANOWorld, an outreach program that focuses on the education, application and use of nanotechnology in the physical and life sciences.

Monday, February 12, 2007

Helios Education Foundation Grant to Support TGen’s 2007 Summer Internship Program

Helios Education Foundation Grant to Support TGen’s 2007 Summer Internship Program

Biotech News

Funding to Seed Training of the Next Generation of Scientists


Phoenix, AZ, February 12, 2007-The Translational Genomics Research Institute (TGen) today announced the award of a $380,000 grant from the Helios Education Foundation to create the Helios Scholars Program at TGen. The program provides stipend funding for 50 qualified high school, undergraduate and graduate students who compete for the opportunity to gain hands-on research experience as summer interns under the guidance of a TGen mentor. The eight-week program supports students from all backgrounds in their efforts to develop foundational skills as they pursue careers in science or medical-related fields.
The Helios Education Foundation, considered the largest education foundation in Arizona, has donated more than $10 million to Arizona's educational programs since its establishment in 2004.

"TGen's summer program allows students from all backgrounds the opportunity to experience and apply the speed and caliber of cutting-edge research as they continue their educational experience. The only prerequisite is a love of science and learning." - Dr. Jeffrey Trent, TGen President

"After meeting with researchers at TGen and learning about TGen's summer internship program, I believe this is an opportunity for Helios to support science education and advance educational opportunities in Arizona," said Vince Roig, Chairman and CEO of the Helios Education Foundation. "We are extremely excited to partner with TGen in its endeavor to train the next generation of genomic scientists."

In addition to the stipends, Helios and TGen recognize each student as a Helios Scholar. The grant also funds an end-of-the-summer symposium where students present their work to their peers, TGen staff, family and guests. Additionally the grant provides six merit-based scholarships totaling $5,200 and supports several extra curricular activities to encourage student interaction and learning.

"We are proud to join with the Helios Education Foundation to create a rich and rewarding educational partnership," said TGen president, Dr. Jeffrey Trent. "TGen's summer program allows students from all backgrounds the opportunity to experience and apply the speed and caliber of cutting-edge research as they continue their educational experience. The only prerequisite is a love of science and learning."

Helios Scholars have the opportunity to work under the mentorship of an experienced investigator, while working side-by-side with TGen researchers and their scientific teams to learn all aspects associated with scientific inquiry. Depending on education level, student stipends range from $3,200 to $4,800.

Last summer, TGen hosted 55 interns with diverse educational backgrounds including bioengineering, biology, business, biochemistry, nursing, speech and hearing science, international studies, business, humanities, family studies, and human development.

Now in its fifth year, the program seeks to broaden its recruitment by focusing on one of the Helios Education Foundation's objectives in this endeavor: identifying and attracting qualified minority and economically disadvantaged students to the study of science.

TGen's past summer interns boast an array of impressive accomplishments, including publishing scientific abstracts and peer-reviewed articles, gaining acceptance into medical and graduate school and winning scholarships and prizes. In 2005, TGen interns Albert Shieh and Anne Lee took first place in the team category at the 2005-2006 Siemens Westinghouse Competition in Math, Science and Technology. The interns split a $100,000 scholarship.

"By investing in the education of students who have a strong interest in science, we are investing in Arizona's future," said Helios President Paul Luna. "Our collaboration with TGen is an example of how we can enrich the learning experiences of students who are interested in science."

Applications for the summer program are accepted on-line through the TGen website. For more information about the Helios Scholars Program at TGen or to fill out an on-line application, students should visit or The application process closes March 23, 2007.

# # #

About TGen
The Translational Genomics Research Institute (TGen), a non-profit 501(c)(3) organization, with a focus on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen bases its research on personalized medicine and the institute plans to accomplish its goals through robust and disease-focused research.

About Helios Education Foundation
Helios Education Foundation (Helios) is an education foundation headquartered in Phoenix, Arizona, serving the citizens of Arizona and Florida with an endowment in excess of $600 million. Helios is dedicated to supporting initiatives that encourage participation, increase access, and enrich the learning experience leading to the successful completion of post-secondary education for Arizona and Florida residents. Helios is an outgrowth of the February 2004 conversion and reorganization of Southwest Student Services Corporation (Southwest), an Arizona not-for-profit corporation, and its not-for-profit affiliates, Arizona Educational Loan Marketing Corporation (AELMAC) and Florida Educational Loan Marketing Corporation (FELMAC). Southwest was a full service provider of student loan products and services to students, families and schools in Arizona, Florida and nationally. For more information about Helios, visit

Saturday, February 10, 2007

Biotechnology Center Awards $1.9 Million to Four Universities The North Carolina Biotechnology Center

The Iranian Disease
By Jamie Stern-Weiner
... combat “anti-Iranian” terrorist groups in Iraq and the US, acknowledge Iran’s “legitimate security interests” in the region and allow Iran “full access to peaceful nuclear technology, biotechnology and chemical technology”. ...

Crude Tools
The greatest advance that stems from modern biotechnology will be the ability to move beyond the hammer approach - and melatonin is very much a hammer approach - to precisely interact with the components of the machinery rather than ...

Evolutionary Methods in Biotechnology: Clever Tricks for Directed ...
By ^^ScOrPiOn^^
From library generation by random or directed mutagenesis to screening and selection techniques - the crucial steps for successful evolutionary biotechnology are described in detail in this practical guide that also includes valuable ...

Biotechnology Center Awards $1.9 Million to Four Universities The North Carolina Biotechnology Center has awarded $1.9 million in grants to four North Carolina universities to boost biotechnology research and teaching collaborations.

US nurtures numerous biotechnology centers

US nurtures numerous biotechnology centers Phoenix Business Journal - Phoenix,AZ,USA A survey of the US biotechnology sector reports the Bay Area is just one of several strong biotech centers nationwide. Although such growth means more ...

Blend of science and commerce
In-Forum (subscription) - Fargo,ND,USA
It also involves taking efficiency lessons from fellow manufacturers whose products seem far removed from the world of biotechnology, such as Fargo Assembly ...

BIO Urges Congress to Further Increase FDA Budget ... Budget

Sunday, February 04, 2007

Leading Algae-Based Biotechnology Companies

Leading Algae-Based Biotechnology Companies in USA and Germany Team Up to Accelerate the Commercialization of Recycling Greenhouse Gases into Biofuels

Greenfuel Technologies Corporation, a leader in the development of algae bioreactor technology for recycling CO2 in flue gases into clean, renewable biofuels, announced that it has signed a strategic alliance agreement with IGV, a private industrial research institute headquartered in Pottsdam, Germany. IGV is a pioneer in micro-algae research and production with more than 80 commercial technology deployments worldwide. The announcement was made today in Pottsdam at a special signing ceremony attended by several Brandenburg government ministers and other high-ranking German dignitaries of science, industry and politics.

Under the terms of the agreement, GreenFuel and IGV will share proprietary algae bioreactor technology in an effort to accelerate the commercialization of biofuel production from recycled carbon dioxide in power plant flue gas emissions. GreenFuel and IGV will also pursue commercial opportunities together in Europe. Once in commercial production, the GreenFuel Emissions-to-Biofuels™ process will allow power plants to significantly reduce carbon dioxide emissions, generate carbon credits, and produce clean, renewable biofuels.

Algae are unicellular plants and, like all plants, they divide and grow using the process known as photosynthesis. GreenFuel estimates that its Emissions-to-Biofuels™ process can absorb a significant percentage of a power plant’s CO2 emissions during the daytime. Unlike typical agricultural biofuel feedstocks, such as soybeans or corn which have a limited harvest window, algae multiply every hour and can be harvested every day. Algae can also be grown on poor quality land with non-potable water, so they don’t compete for land suitable for food crops. The carbon-enriched algae contain lipid oils and starches that can be converted into biodiesel and ethanol for transportation fuels. The residual protein can be used for animal feed and nutritional supplements. GreenFuel is currently involved in a number of Emissions-to-Biofuels™ pilot projects in the USA, Australia, Europe, and South Africa.

“We are extremely impressed with the knowledge, experience and professionalism of the entire IGV organization,” said Cary Bullock, CEO of GreenFuel Technologies Corporation. “We believe that IGV will be a valuable and strategic partner in our efforts to bring our Emissions-to-Biofuels™ algal bioreactor systems into full-scale commercial production at a number of locations around the world.”

About GreenFuel Technologies Corporation

With more than a dozen pending patents, GreenFuel Technologies Corporation is a recognized leader in the development of algae bioreactor systems that recycle carbon dioxide into clean renewable biofuels. GreenFuel Technologies Corporation is winner of both the “2006 Platts Global Energy Award for Energy Emission Project of the Year,” and the “2006 Frost & Sullivan Innovation of the Year Award – Biofuels.” Founded in 2001, the company is headquartered in Cambridge, Massachusetts. For more information, visit

Biotech News
Biotech Marketing

Biotechnology in the United States

A Five-Year Forecast Of The Biotechnology Industry In The United States
Research and Markets ( has announced the addition of “Biotechnology in the United States” to their offering.

Our Biotechnology in the United States industry profile is an essential resource for top-level data and analysis covering the biotechnology industry. It includes detailed data on market size and segmentation, plus textual analysis of the key trends and competitive landscape, demographic information, and descriptions of the leading companies.

Scope of this title:

Contains an executive summary and data on value, volume and segmentation
Provides textual analysis of the industry’s prospects, competitive landscape and leading companies
Includes a five-year forecast of the industry
Supported by the key macroeconomic and demographic data affecting the market
Why you should buy this report
Spot future trends and developments
Inform your business decisions
Add weight to presentations and marketing materials
Save time carrying out entry-level research
Market Definition

The biotechnology market consists of the development, manufacturing and marketing of products based on advanced biotechnology research. The market value reflects revenues of companies within this industry from product sales, licensing fees, royalties and research funding. Any currency conversions used in the creation of this report have been calculated using constant 2004 annual average exchange rates.

Biotech News
Biotech Marketing

For the purposes of this report, Europe consists of Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom, Bulgaria, Czech Republic, Hungary, Poland, Romania, Russia, Slovakia and the Ukraine.

Asia-Pacific consists of China, Hong Kong, India, Japan, Malaysia, Singapore, South Korea, Vietnam, Australia and New Zealand.

The global market is composed of Europe, Asia-Pacific, US, Canada, Turkey, Argentina, Brazil, Chile, Colombia, Mexico, Algeria, Egypt, Israel, UAE, Saudi Arabia and South Africa.

Topics Covered:

Market overview
Market value
Market segmentation
Competitive landscape
Leading companies
Market forecasts
Macroeconomic indicators
Companies Mentioned:

Amgen Inc.
Applied Biosystems
Biogen Idec, Inc.
Chiron Corporation
Genentech, Inc.
Biogen Idec, Inc.
MedImmune, Inc.

Biotechnology News

Empires of the Mind: The Emergence of the Biotechnology Industry Inside Collin County Business - Plano,TX,USA Although their new firm, Genentech, did not have a product in the marketplace for years, the world's first biotechnology company had been christened. ...

BIOTECHNOLOGY: Monsanto, Divergence extend nematode deal St. Louis Post-Dispatch - St. Louis,MO,USA Monsanto Co. and Divergence Inc., both based in Creve Coeur, said Wednesday that they are making progress in the fight against soybean cyst nematodes, ...

Leading Algae-Based Biotechnology Companies in USA and Germany ... - USA
(CSRwire) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2007--Greenfuel Technologies Corporation, a leader in the development of algae bioreactor technology ...

Not one but four biotechnology deals for Pfizer Pharma Times (subscription) - London,UK ... world of major acquisitions, for the moment at least, and has entered into four new alliances in a bid to find some pearls in the biotechnology basket. ...

Lixte Biotechnology to Obtain High-Quality Tissue and Blood ...
Primenewswire (press release) - Los Angeles,CA,USA 11, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Lixte Biotechnology Holdings, Inc.
announced today that its wholly owned subsidiary, Lixte Biotechnology, Inc., ...

Wyeth partners with SF schools
Ft. Washington Montgomery Newspapers - Fort Washington,PA,USA Wyeth Pharmaceuticals and the Biotechnology Institute have partnered with local schools to allow Wyeth scientists to share their knowledge of biotechnology ...

Profit up 75% at No. 2 biotechnology company Asbury Park Press - Asbury Park,NJ,USA Genentech Inc., the world's second-biggest biotechnology company, said Wednesday that fourth-quarter profit rose 75 percent, helped by surging sales of a ...

Eli Lilly Abandons Prince William Project Washington Post - Washington,DC,USA The employees, who occupy several trailers on the site, range from low-level technical support staff to scientists and biotechnology specialists helping ...

Lixte Biotechnology to Obtain High-Quality Tissue and Blood ...
EAST SETAUKET, NY, Jan. 11, 2007 (PRIME NEWSWIRE) -- Lixte Biotechnology Holdings, Inc.

RedOrbit News - Health

Profit up 75% at No. 2 biotechnology company Genentech Inc., the world's second-biggest biotechnology company, said Wednesday that fourth-quarter profit rose 75 percent, helped by surging sales of a new treatment for age-related vision loss and expanded use of the Avastin cancer ... - Business

House to pass stem cell research bill (AP) By Yahoo! News: Biotechnology News Sen. Tom Harkin, D-Iowa, second from left, holds up a AP - Their ranks bolstered by the November elections, supporters of legislation boosting taxpayer-funded research on embryonic stem cells were poised to easily pass the bill again ...

Biotech Industry

Lixte Biotechnology to Obtain High-Quality Tissue and Blood ...
11, 2007 (PRIME NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. announced today that its wholly owned subsidiary, Lixte Biotechnology, Inc., entered into an agreement with the Institute of Pathology at the University of Regensburg in ...


Scientists debate modern biotechnology
Accra - Professor Emmanuel Owusu-Bennoah, Director-General of the Council for Scientific and Industrial Research (CSIR), on Wednesday bemoaned the decreasing prioritization of science and technology at the national level as reflected in ...

Hi Ghana

Biotech News

From the Editor: Cloning and Biotech Progress Bio Pharm - Fords,NJ,USA But as members of the biotech community, we must evaluate each biotech application on its own merit. We should support the forward march of science not just ...

Biotech program gets pushed on the Hill
Salt Lake Tribune - Salt Lake City,UT,USA As it stands, high school juniors and seniors take biotech classes and participate in internships through the Jordan Applied Technology Center on SLCC's ...

ACTC's Lanza wins biotech award
Worcester Business Journal - Worcester,MA,USA The award, for "Outstanding Contribution in Contemporary Biology, was given to Lanza at the organization's 5th Annual Biotech Expo at Brown's Providence ...

Biotech Day in Review: AstraZeneca Buys Arrow Therapeutics Seeking Alpha - New York,NY,USA Centient Biotech Investor submits: AstraZeneca (AZN) continues to be in the spotlight. After announcing two drug development deals potentially worth up to ...

Biofusion Launches Absynth Biologics to Focus on New Treatments ...
Biofusion plc, the university IP commercialisation company, announced the launch of a new portfolio company, Absynth Biologics Ltd, which will develop vaccines and antibodies to treat infections ...

Biotech Roundup: Feed Me, PDUFA IV, One More Reason to Watch The ...
Feed MeBig pharma and biopharma continue to scratch their pipeline itch this week AstraZeneca AZN buys UK firm Arrow Therapeutics and Pfizer PFE is buying BioRexis Pharmaceuticals Going a slightly different route Sanofi SNY may or may ...

Mediatech Becomes Exclusive Supplier for Rapak Biotech Aseptic ...
Mediatech Becomes Exclusive Supplier for Rapak Biotech Aseptic Filling System

New blog for Biotech Jobs
By C.M Russell(C.M Russell)
Clifford Mintz, of BioInsights, offering services related to bioscience and biotech careers, pharmaceutical and science jobs. Also offering the services of science career development, biotech career development advice, ...

Obesity Drug new Cancer Solution
We've known for years now that obese people are more at risk for developing cancer, now not only the cause but also the treatment may be "shared".

Arizona Biotech News
Biotech Marketing

Biotech News

Trinity Biotech in New York clinic deal
Biotechnology Ireland - Dublin,Ireland
Medical diagnostics firm, Trinity Biotech, today said it has entered a strategic partnership with Community Healthcare Network (CHN) of New York City to ...

Biotech Roundup: Feed Me, PDUFA IV, One More Reason to Watch The ... - New York,USA
Big pharma and biopharma continue to scratch their pipeline itch this week.
AstraZeneca (AZN) buys UK firm Arrow Therapeutics and Pfizer (PFE) is buying ...

Mediatech Becomes Exclusive Supplier for Rapak Biotech Aseptic ...
Genetic Engineering News (press release) - New Rochelle,NY,USA Mediatech and Rapak entered into a business agreement for the exclusive marketing and sale of aseptic filling equipment and filling glands, ...

Quotes Famous Quotes Famous Quotes

Biotech & Medical Venture Deals Roundup

Biotech issues morph meeting
Capital Press (subscription) - Salem,OR,USA Peterson said USW will continue on its own to develop strategies for the introduction of biotech traits in wheat. A focus that appears to resonate for wheat ...

Biotech & Medical Venture Deals Roundup
by Adam Rubenstein Claros Diagnostics (Woburn, MA) is developing a handheld disease monitoring device that allows anyone to perform laboratory-quality blood tests in any setting, has closed a $7.8M Series A financing. ...

BioHealth Investor

[TNTvillage org]Biotech Ebooks pack1
Seeds: 1 Peers: 3 Filesize: 201 mb.


Human metabolism recreated in lab
US researchers say they have created a "virtual" model of all the biochemical reactions that occur in human cells. BBC NEWS | Health | Human metabolism recreated in lab.

BioBOOM™ - The BioTech Blog

First biogeneric therapeutic protein from Fraunhofer Institute ...
Interferon-beta is used for multiple sclerosis therapy. An interferon-beta protein developed at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart, Germany, in ... daily News from Biotech-...

Adult Stem Cell Biotech and Industry
One of the most famous companies is Osiris Therapeutics Inc. Osiris Therapeutics has three products in clinical trials: Prochymal™ is finishing phase III of clinical trials for the treatment of steroid-refractory acute Graft vs. ...

Biomedical Sciences Blog

Famous Quotes

Biotech pharma plant to be set up

Biotech pharma plant to be set up
Daily Times - Lahore,Pakistan
The initiative is being taken in the field of medicine by the private sector in collaboration with investors from two advanced biotech South American ...

UF professor's biotech firm graduates
Gainesville Sun - Gainesville,FL,USA
Encor Biotechnologies is now the latest biotech company to graduate from the University of Florida's Sid Martin Biotechnology Development Incubator in ...

Students get peek into biotech field
Inside Bay Area - Oakland,CA,USA
Twenty-seven students from Carlmont High School toured the campuses of biotech pioneer Genentech and upstart Cell Genesys in South San Francisco as part of ...

Feuerstein's Biotech Mailbag - USA
Welcome to the "biotech mailbag." I get a lot of great reader email and feedback -- keep the email coming -- which I try hard to answer directly.

Famous Quotes

Biotech News - Maine Biotechnology Services: Got Antibody Development?

Maine Biotechnology Services: Got Antibody Development?
By Rich Brooks
If so, you'll want to check out flyte's most recent launch, Maine Biotechnology Services. MBS has a long history of strong working relationships with customers, providing excellent technical advice, and superior support. ...

Small Cap Portfolio, ABR20SC Established on February 1, 2007 ...
We established a new portfolio on February 1, 2007 of biotechnology stocks under
$1 billion..

Biotechnology Investing | Biotech...

Making tough choices in biotechnology

Making tough choices in biotechnology
By George Elvin
“The ongoing political debate over the appropriate use of embryonic stem cells and the low level of government support have denied stem cell research the catalyst provided to biotechnology,” say the article’s authors. ...

"Smokable" pain drugs promise faster action By Oceaneyes2 Alexza was formed by biotechnology entrepreneur Alejandro Zaffaroni, who also founded nicotine-patch developer Alza. His latest venture is not the only company that is developing inhaled therapies: Nektar Therapeutics and Alkermes Inc. ...

Deadline Extended for Innovation Corridor Submissions at the 2007 ...
... Extended for Innovation Corridor Submissions at the 2007 BIO International Convention
extended-for-innovation-corridor-submissions-at-the-2007-bio-international. ...

ADN1.COM Category: Biotechnology

Weblog Awards

Wyeth to Present at the Merrill Lynch 2007 Global Pharmaceutical, Biotechnology and Medical Device Conference

Wyeth to Present at the Merrill Lynch 2007 Global Pharmaceutical, Biotechnology and Medical Device Conference

Wyeth (NYSE: WYE) announced today that it will present at the Merrill Lynch 2007 Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, February 7, 2007 at 9:20 a.m. Eastern Time. Presenting for Wyeth will be Robert Essner, Chairman and Chief Executive Officer.

Wyeth's presentation will be webcast live for investors at and available for replay following the conference.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.